BioPharmX Corp BPMX Cash Flow

Biopharmx corp (BPMX)

CashFlow / Quarterly

Jan'20	Oct'19	Jul'19	Apr'19	Jan'19	Oct'18	Jul'18	Apr'18	Jan'18	Oct'17	Jul'17	Apr'17	Jan'17	Oct'16	Jul'16	Apr'16	Jan'16	Oct'15	Jul'15	Apr'15	Dec'14	Sep'14	Jul'14	Jun'14	Apr'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10
Cash flows from operating activities:
Net loss
-1,305	-2,113	-2,646	-3,623	-4,056	-4,390	-4,410	-4,402	-3,788	-3,714	-3,741	-5,397	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-53	-1	-2	-2
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4,461	-4,553	-3,850	-3,571	-3,624	-2,776	-2,065	-	-1,813	-1,335	-1,153	-766	-451	-262	-109	-	-	-	-	-	-	-	-	-
Net loss for the period
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-45	-1	-2	-2	-19	-1	-5	-1	-	-	-	-
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
144	229	177	191	304	718	446	593	471	465	566	385	447	347	424	273	348	242	324	300	808	72	-	281	115	32	30	17	6	5	-	-	-	-	-	-	-	-	-
Fair value of modification of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	436	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation expense
15	16	16	14	14	15	17	16	14	14	12	12	90	18	17	16	20	15	13	8	15	6	-	3	2	1	-1	2	3	1	0	0	0	0	0	0	0	0	0
Amortization expense
-	-	-	-	-	-	-	-	-	-	-	-	97	7	8	7	8	7	8	7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	25	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of warrant liability
-	0	2	9	-	42	23	-66	34	169	525	-364	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Noncash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	6	-	70	-	30	6	6	-	-	-	-	-	-	-	-	-
Changes in assets and liabilities:
Accounts receivable
-	-	-	-	-	-	-	-	-	6	-1	-1	-	-	-5	-1	-2	-24	27	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inventories
-	-	-	-	-	-	-	-	-	-5	-10	-8	-39	-35	36	-24	-236	-28	149	55	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other assets
-138	-92	233	-66	-125	-147	355	-51	-364	104	229	-44	-	-	-	-	6	-135	-721	896	-33	-185	-	332	265	19	-375	191	0	0	-	-	-	-	-	-	-	-	-
Accounts payable
-123	-250	-248	-178	-24	-139	-266	416	-630	-364	62	-243	-284	-581	1,022	617	16	-1,568	1,085	1,092	-	-	73	-	197	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued expenses and other liabilities
-304	-215	-281	206	-710	142	251	-344	-101	231	-303	600	-736	810	156	-74	238	-193	131	432	-	-	-	-	-	-	-	45	1	0	-3	19	-1	1	-2	53	1	1	-2
Accrued expenses and other liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	59	-	-29	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	552	-	287	-	50	335	30	17	64	-	-	-	-	-	-	-	-	-
Payroll
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-51	38	-	34	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Related party payables
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	56	-57	-48	56	-146	52	-	105	97	63	-14	125	-2	0	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3,597	-3,635	-5,217	-1,513	-2,249	-	-	-1,318	-	-1,159	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase in accrued interest - related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	-	-	-	-
Net cash used in operating activities
-1,316	-2,241	-3,217	-3,333	-3,499	-3,549	-4,340	-3,604	-3,723	-3,491	-4,147	-4,226	-	-	-	-	-	-	-	-	-	-1,177	-	-1,364	-	-956	-410	-405	-232	-33	-5	0	-3	-3	-4	4	-4	-1	-4
Cash flows from investing activities:
Purchases of property and equipment
0	0	24	6	30	9	0	4	0	13	18	10	25	-1	16	5	-	-	-	-	62	145	-	11	9	10	1	14	10	0	0	0	0	0	0	1	-0	0	-0
Net cash used in investing activities
0	0	-24	-6	-30	-9	0	-4	0	-13	-18	-10	-	-	-	-	-	-	-	-	-	-145	-	-46	-	-10	-11	-14	-10	-50	-	-	-	-	-	-	-	-	-
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of issuance costs
0	389	3,257	3,554	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-
Purchase of intellectual property
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10	0	0	50	-	-	-	-	-	-	-	-	-
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5	-	-	-	-	-	-	-183	-	-9	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the issuance of common stock, preferred stock and warrants, net of issuance costs
-	-	-	-	-	-	-	-	9,694	0	1,911	4,444	11,037	2,092	0	3,583	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	15	0
Proceeds from exercises of common stock warrants
-	-	-	-	3,585	0	0	6,961	-	-	-	-	-	-	-	-	-25	0	100	1,412	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercises of stock options
0	0	0	4	0	0	0	1	-	-	-	-	0	16	7	18	35	23	14	11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments on financing lease obligation
9	11	9	5	5	5	5	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from issuance of convertible redeemable preferred stock and common stock warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,032	-	1,456	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repurchase of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-
Proceeds from issuance of convertible notes, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	280	1,020	400	373	207	50	3	-	0	0	0	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,601	5,505	23	8,435	1,423	-	-	1,032	-	1,736	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
616	378	3,248	3,553	3,580	-5	-5	6,958	9,723	615	1,921	4,444	-	-	-	-	-	-	-	-	-	1,656	-	2,227	-	1,020	400	373	207	50	3	-	-	-	0	-	-	-	-
Net decrease in cash and cash equivalents
-700	-1,863	7	214	51	-3,563	-4,345	3,350	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash investing activities:
Net increase (decrease) in cash and cash equivalents
-	-	-	-	-	-	-	-	6,000	-2,889	-2,244	208	6,033	32	-3,602	-1	1,858	-5,207	6,909	-826	903	334	-	817	568	54	-21	-46	-35	-33	-	-	-	-	-	-	-	-	-
Supplemental disclosures:
Interest paid
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0
Income taxes paid
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0
NET INCREASE IN CASH
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0	-0	-1	-2	0	-3	-3	-4	5	-5	13	-5